Automated Hemoglobin Testing System

A new automated hemoglobin testing system and A1c test kit are designed to monitor existing as well as newly diagnosed patients with diabetes. The system has been cleared by the U.S. Food and Drug Administration (FDA).

Called Variant II Turbo hemoglobin testing system and hemoglobin A1 test kit, the system was developed by Bio-Rad Laboratories, Inc. (Hercules, CA, USA). The fully automated system complements the company's existing diabetes monitoring offerings and will enable clinical laboratories to increase throughput, improve workflow efficiencies, and provide faster results to healthcare providers and their patients, according to Bio-Rad.

"We are pleased to introduce the new Variant II Turbo at a time when demand for diabetes testing is on the rise,” said John Goetz, vice president of clinical diagnostics, Bio-Rad. "This new system delivers superior performance and will provide clinical laboratories with the added capabilities and throughput required to quickly and accurately monitor patients with existing and newly diagnosed diabetes.”

According to the American Diabetes Association, more than 18 million Americans suffer from diabetes, but one-third of those people are unaware of their condition. To combat this problem, the U.S. Department of Health and Human Services recently spearheaded a program, the Diabetes Detection Initiative, to identify this population through increased testing.




Related Links:
Bio-Rad